查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
在线药房 (ePharmacy)：主要趋势、区域分析和市场预测 (2022-2027)
市场调查报告书
商品编码
1134406

在线药房 (ePharmacy)：主要趋势、区域分析和市场预测 (2022-2027)

ePharmacy: Key Trends, Regional Analysis and Market Forecasts 2022-2027
出版日期: | 出版商: Juniper Research Ltd | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

全球在线药店用户数量预计将从 2022 年的 7.95 亿增长到 2027 年的 10 亿，增长 28%。这一增长被认为是由于 COVID-19 大流行迫使消费者呆在家里并通过在线药店取药而导致采用率激增的结果。我们预计，随着供应商专注于通过改进在线药店提供的效率和便利性来维持和扩大其客户群，我们预计将继续增长。

  • 消费者将继续使用在线药店，因为他们认识到在线药店提供的药品价格实惠以及与实体药店相比具有更广泛的选择等优势。
  • 将通过简化在线流程来维持在线药店的增长。这可以通过消除纸质处方来实现，因为电子处方越来越被广泛接受。
  • 在线药房服务将继续大量用于非处方药（OTC）药品。预计2027年全球场外交易量将达到89亿笔，占全球交易总额的64%。另一方面，全球处方交易数量为 50 亿。由于消费者对交付准确性、时间和错过交付的担忧，处方的数字化将被推迟。为了解决这些问题并抵消非法在线药店的兴起，实时跟踪和加强对在线药店的监管应该是确保未来增长的优先事项。

本报告分析了全球在线药房 (ePharmacy) 市场，包括市场的基本结构、在发达国家/新兴国家的渗透率、主要市场驱动因素以及整体市场规模趋势预测（用户数量、交易数量、金额未来五年的交易）、按行业（处方药、OTC）和地区（共 60 个国家）的详细趋势、市场竞争结构、未来增长潜力和挑战、主要公司 我们正在调查（15公司总数）。

回答的主要问题

  • 1. 主要市场趋势将如何影响在线药店？
  • 2. OTC（非处方药）和处方药之间的在线药店有何不同？
  • 3. 在线药房市场的主要供应商有哪些？
  • 4. 阻碍网上药店的製约因素有哪些？
  • 5. 在线药店在哪些地区最成功？

主要特点

  • 基准行业预测：按地区（共 8 个地区）、按国家/地区（共 60 个国家/地区）
    • 北美
      • 加拿大、美国
    • 拉丁美洲
      • 阿根廷、巴西、智利、哥伦比亚、厄瓜多尔、墨西哥、秘鲁、乌拉圭
    • 西欧
      • 奥地利、比利时、丹麦、芬兰、法国、德国、希腊、爱尔兰、意大利、荷兰、挪威、葡萄牙、西班牙、瑞典、瑞士、英国
    • 中欧和东欧
      • 克罗地亚、捷克共和国、匈牙利、波兰、罗马尼亚、俄罗斯、土耳其、乌克兰
    • 远东/中国
      • 中国、香港、日本、韩国
    • 印度次大陆
      • 孟加拉国、印度、尼泊尔、巴基斯坦
    • 其他亚太国家
      • 澳大利亚、印度尼西亚、马来西亚、新西兰、菲律宾、新加坡、泰国、越南
    • 非洲/中东
      • 阿尔及利亚、埃及、以色列、肯尼亚、科威特、尼日利亚、卡塔尔、沙特阿拉伯、南非、阿拉伯联合酋长国

分析的公司

  • Juniper Research Competitor Leaderboard对象企业：1mg、Amazon Pharmacy、Apollo Pharmacy、CVS Health、DocMorris、Express Scripts、Giant Eagle、Lloyds Pharmacy、Netmeds、Optum、Rowlands Pharmacy、The Kroger、Walgreens Boots Alliance、Walmart、Well Pharmacy
  • 言及企业：Accredo、Adipositas Care、Adobe、Aetna、Bajaj Allianz、Bakers、Berkshire Hathaway、Blue Cross Blue Shield、Braze、CareCentrix、CareContinum、CareZone、Chefaa、City Market Food and Pharmacy、Copps、CuraScriptSD、Deliveroo、Ecrebo、Epic、Evicore Healthcare、Famhealth、FredMeyer、Freedom Fertility Pharmacy、Frys、HasHealth、Haven、HDFC、Horizon、ICICI Bank、Inside Rx、JPMorgan Chase、KiviHealth、Lazada Philippines、Lyf、Mamajan Imaging、Max Bupa、MedAvail、Medbase、Mesmerize、Microsoft、MyMatrixx、NCotably、Novo Nordisk、Omnicell、Onofre、Patanjali、PathCare、PAYBACK、PillPack、Practio、Prime Therapeutics、Raia Drogasil SA、SBI、Shopee Philippines、Signify Health、Target Pharmacies、Tata Digital、TeleClinic、Thyrocare、Verizon、Willons、Yodawy、ZEE5、Zur Rose Group.

内容

第 1 章分析概述和战略建议

第2章现状与展望

  • 在线药房生态系统：概览
    • 在线药店的类型
      • 数字专卖店
      • 实体店的数字孪生
    • 电子处方
  • 在线药店的好处
    • 对消费者的好处
      • 节省时间
      • 降低成本
      • 效率
      • 个性化
      • 选择范围
    • 对公司的好处
      • 节省时间
      • 最大化利润
      • 对政府的好处
  • 主要市场驱动因素分析
  • 限制因素

第3章区域分析

  • 区域分析
    • 北美
      • 美国
      • 加拿大
    • 拉丁美洲
      • 墨西哥
      • 巴西
    • 西欧
      • 德国
      • 英国
    • 中欧和东欧
      • 波兰
      • 土耳其
    • 远东/中国
      • 中国
      • 韩国
    • 印度次大陆
      • 印度
      • 巴基斯坦
    • 亚太地区
      • 澳大利亚
      • 菲律宾
    • 非洲/中东
      • 埃及
      • 阿拉伯联合酋长国

第 4 章竞争对手排行榜和供应商简介

  • 在线药房：供应商资料
    • 1mg
      • 公司
      • 地区
      • 主要客户和合作伙伴
      • 高级产品/服务
      • JuniperResearch 洞察：主要优势和战略机遇
    • Amazon Pharmacy
    • Apollo Pharmacy
    • CVS Pharmacy
    • DocMorris
    • Express Scripts
    • Giant Eagle
    • Lloyds Pharmacy
    • Netmeds
    • Optum
    • Rowlands Pharmacy
    • The Kroger
    • Walgreens Boots Alliance
    • Walmart
    • Well Pharmacy

第5章市场预测

  • 简介
    • 在线药房处方药：一种预测性研究方法
    • 在线药店的 OTC（非处方药）：一种预测性研究方法
    • 在线药店交易总数
    • 网上药店的总交易额
    • 在线药店总收入
简介目录

Juniper Research's “ePharmacy” report provides a detailed evaluation of the market, including the adoption of ePharmacy within both developing and established markets. In addition, this report covers market opportunities; providing strategic insights into the technologies and key drivers that are pushing the space forward, and the role of 15 leading ePharmacy vendors across the market.

The research suite also contains a detailed dataset; providing forecasts for 60 countries across a number of different metrics, including the number of ePharmacy users, number of ePharmacy transactions, number of OTC (Over the Counter) and prescription transactions through ePharmacy and total ePharmacy revenue.

This research suite comprises of:

  • Strategy & Forecasts (PDF)
  • 5-year Market Sizing & Forecast Spreadsheet (Excel)
  • 12 Months Access to harvest Online Data Platform

KEY FEATURES

  • Market Dynamics: A strategic analysis of the major drivers, challenges, and innovations shaping the adoption and development of ePharmacy technologies, including the following:
    • COVID-19 impact on the ePharmacy market
    • Future strategic direction and market outlook for ePharmacy
    • Key issues ePharmacy vendors must be aware of surrounding legislation and data sharing
  • Regional Analysis: A regional-level analysis of 16 countries, spanning 8 key regions; covering the current deployment level and future outlook of ePharmacy in each market.
  • Key Takeaways & Strategic Recommendations: Analysis of key development opportunities within ePharmacies, accompanied by key strategic recommendations for stakeholders.
  • Benchmark Industry Forecasts: Includes forecasts for total number of ePharmacy users, total annual spend on ePharmacy, total fee revenue from ePharmacy, total transaction value from ePharmacy. Total number of transactions and revenue split by OTC and prescription medication. This data is split by our 8 key forecast regions and 60 countries:
    • North America:
      • Canada, US
    • Latin America:
      • Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
    • West Europe:
      • Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK
    • Central & East Europe:
      • Croatia, Czech Republic, Hungary, Poland, Romania, Russia, Turkey, Ukraine
    • Far East & China:
      • China, Hong Kong, Japan, South Korea
    • Indian Subcontinent:
      • Bangladesh, India, Nepal, Pakistan
    • Rest of Asia Pacific:
      • Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam
    • Africa & Middle East:
      • Algeria, Egypt, Israel, Kenya, Kuwait, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates
  • Juniper Research Competitor Leaderboard: Key player capability and capacity assessment for 15 ePharmacy vendors:
    • 1mg
    • Amazon Pharmacy
    • Apollo Pharmacy
    • CVS Health
    • DocMorris
    • Express Scripts
    • Giant Eagle Pharmacy
    • Kroger
    • Lloyds Pharmacy
    • Netmeds
    • Optum
    • Rowlands Pharmacy
    • Walgreens Boots Alliance
    • Walmart
    • Well Pharmacy

KEY QUESTIONS ANSWERED

  • 1. How will key market trends affect ePharmacy?
  • 2. How will ePharmacy differ for over-the-counter and prescription medication?
  • 3. Who are the leading vendors in the ePharmacy market?
  • 4. What limitations are holding back ePharmacy?
  • 5. What regions will ePharmacy be most successful in?

COMPANIES REFERENCED

  • Included in the Juniper Research Competitor Leaderboard: 1mg, Amazon Pharmacy, Apollo Pharmacy, CVS Health, DocMorris, Express Scripts, Giant Eagle, Lloyds Pharmacy, Netmeds, Optum, Rowlands Pharmacy, The Kroger, Walgreens Boots Alliance, Walmart, Well Pharmacy.
  • Mentioned: Accredo, Adipositas Care, Adobe, Aetna, Bajaj Allianz, Bakers, Berkshire Hathaway, Blue Cross Blue Shield, Braze, CareCentrix, CareContinum, CareZone, Chefaa, City Market Food and Pharmacy, Copps, CuraScriptSD, Deliveroo, Ecrebo, Epic, Evicore Healthcare, Famhealth, FredMeyer, Freedom Fertility Pharmacy, Frys, HasHealth, Haven, HDFC, Horizon, ICICI Bank, Inside Rx, JPMorgan Chase, KiviHealth, Lazada Philippines, Lyf, Mamajan Imaging, Max Bupa, MedAvail, Medbase, Mesmerize, Microsoft, MyMatrixx, NCotably, Novo Nordisk, Omnicell, Onofre, Patanjali, PathCare, PAYBACK, PillPack, Practio, Prime Therapeutics, Raia Drogasil SA, SBI, Shopee Philippines, Signify Health, Target Pharmacies, Tata Digital, TeleClinic, Thyrocare, Verizon, Willons, Yodawy, ZEE5, Zur Rose Group.

DATA & INTERACTIVE FORECAST

Juniper Research's “ePharmacy” forecast suite includes:

  • Prescription Medication
  • Over-the-Counter Medication

Metrics including total number of transactions completed through ePharmacy, total annual spend on ePharmacy, total revenue through ePharmacy transactions, total revenue through ePharmacy fees, split by OTC and prescription medication.

  • Geographical splits: 60 countries
  • Number of tables: Over 31 tables
  • Number of datapoints: Over 23,500 datapoints
  • harvest: Our online data platform, harvest, contains the very latest market data and is updated throughout the year. This is a fully featured platform enabling clients to better understand key data trends and manipulate charts and tables; overlaying different forecasts within the one chart - using the comparison tool. Empower your business with our market intelligence centre, and receive alerts whenever your data is updated.
  • Interactive Excels (IFxl): Our IFxl tool enables clients to manipulate both forecast data and charts, within an Excel environment, to test their own assumptions using the interactive scenario tool and compare selected markets side by side in customised charts and tables. IFxls greatly increase a client's ability to both understand a particular market and to integrate their own views into the model.

FORECAST SUMMARY

The number of ePharmacy users will reach 1 billion globally by 2027; increasing from 795 million in 2022, a growth of 28%. The research identified this increase as the culmination of surging adoption resulting from the COVID-19 pandemic, where consumers were unable to leave their homes and turned to receiving medication through ePharmacies. Growth will continue, as vendors focus on retaining and expanding their customer bases through refining the efficiency and simplicity that ePharmacy provides.

  • Consumers will continue to utilise ePharmacies as they realise the benefits it provides them, including affordability of medication, and a wider range of choice compared to bricks-and-mortar pharmacies.
  • ePharmacy growth will be sustained by simplifying the online process. This can be achieved through more widespread acceptance of ePrescriptions; eliminating paper copies of their prescriptions.
  • ePharmacy services will continue to be predominantly utilised for OTC (Over-the-Counter) medication. OTC transactions will reach 8.9 billion globally in 2027, accounting for 64% of total global transaction value. This is compared to 5 billion prescription transactions globally in the same year. Prescription digitisation will lag behind due to consumer concerns around delivery accuracy, timing and missed deliveries. In order to allay these concerns and offset the abundance of illegitimate ePharmacies, real-time tracking and stronger regulations for ePharmacies should be priorities to secure future growth.

Table of Contents

1. Key Takeaways & Strategic Recommendations

  • 1.1. Key Takeaways & Strategic Recommendations
  • 1.2. Strategic Recommendations

2. Current Status & Future Outlook

  • 2.1. Overview of ePharmacy Ecosystem
    • Figure 2.1: Visualisation Showing ePharmacy Stages
    • 2.1.1. Types of ePharmacy
      • i. Digital-only Stores
      • ii. Digital Twin of Bricks-and-Mortar
    • 2.1.2. ePrescribing
      • Figure 2.2: Visualisation of ePrescribing
  • 2.2. Benefits of ePharmacy
    • 2.2.1. Benefits for Consumers
      • i. Time Saving
      • ii. Cost Savings
      • iii. Efficiency
      • iv. Personalisation
      • v. Range of Choice
    • 2.2.2. Benefits for Corporations
      • i. Time Saving
      • ii. Maximise Profit Margin
        • Figure 2.3: Visualisation Showing Benefits for Corporates
      • iii. Benefits for Governments
  • 2.3. Exploration of Key Market Drivers
  • 2.4. Limitations

3. Regional Analysis

  • 3.1. Regional Analysis
    • 3.1.1. North America
      • i. US
      • ii. Canada
    • 3.1.2. Latin America
      • i. Mexico
      • ii. Brazil
    • 3.1.3. West Europe
      • i. Germany
      • ii. UK
    • 3.1.4. East & Central Europe
      • i. Poland
      • ii. Turkey
    • 3.1.5. Far East & China
      • i. China
      • ii. South Korea
    • 3.1.6. Indian Subcontinent
      • i. India
      • ii. Pakistan
    • 3.1.7. Asia Pacific
      • i. Australia
      • ii. Philippines
    • 3.1.8. Africa & Middle East
      • i. Egypt
      • ii. United Arab Emirates

4. Competitor Leaderboard and Vendor Profiles

  • Table 4.1: Juniper Research Competitor Leaderboard: ePharmacy Vendors Included & Product Portfolio
  • Figure 4.2: Juniper Research Leaderboard: ePharmacy Vendors
  • Table 4.3: Juniper Research Leaderboard: ePharmacy Vendors & Positioning
  • Table 4.4: Juniper Research Leaderboard Heatmap: ePharmacy Vendors
  • 4.1. ePharmacy - Vendor Profiles
    • 4.1.1. 1mg
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.2. Amazon Pharmacy
      • i. Corporate Information
        • Table 4.5: Amazon's Select Financial Information ($bn), FY2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.3. Apollo Pharmacy
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.4. CVS Pharmacy
      • i. Corporate Information
        • Table 4.6: CVS Health Corporation's Select Financial Information ($bn), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.5. DocMorris
      • i. Corporate Information
        • Table 4.7: Zur Rose's Select Financial Information ($bn), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.6. Express Scripts
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.7. Giant Eagle
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.8. Lloyds Pharmacy
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
        • Figure 4.8: Visualisation of Lloyds Direct App
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.9. Netmeds
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.10. Optum
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.11. Rowlands Pharmacy
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
        • Figure 4.9: Rowlands Pharmacy Hey Pharmacist
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.12. The Kroger
      • i. Corporate Information
        • Table 4.10: Kroger's Select Financial Information ($bn), FY2020-2022 (FYE 31st January)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-Level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.13. Walgreens Boots Alliance
      • i. Corporate Information
        • Table 4.11: Walgreens Boots Alliance's Select Financial Information ($bn), FY2019-2021 (FYE 30th August)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.14. Walmart
      • i. Corporate Information
        • Table 4.12: Walmart's Select Financial Information ($bn), FY 2020-2022 (FYE 31st January)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.15. Well Pharmacy
      • i. Corporate Information
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
        • Table 4.13: Juniper Research Competitor Leaderboard Scoring Criteria

5. Market Forecasts

  • 5.1. Introduction
    • 5.1.1. ePharmacy Prescription Forecast Methodology
    • 5.1.2. ePharmacy OTC Forecast Methodology
      • Figure 5.1: ePharmacy Prescription Revenue Methodology
      • Figure 5.2: ePharmacy OTC Revenue Methodology
    • 5.1.3. Total ePharmacy Transactions
      • Figure & Table 5.3: Total ePharmacy Transactions (m), Split by 8 Key Regions, 2022-2027
      • Table 5.4: Total ePharmacy Transactions, Split by Prescription and OTC Medication
    • 5.1.4. Total ePharmacy Transaction Value
      • Figure & Table 5.5: Total ePharmacy Transaction Value ($m), Split by 8 Key Regions, 2022-2027
      • Table 5.6: Total ePharmacy Transaction Value, Split by Prescription and OTC Medication
    • 5.1.5. Total ePharmacy Revenue
      • Figure & Table 5.7: Total ePharmacy Revenue ($m), Split by 8 Key Regions, 2022-2027
      • Table 5.8: Total ePharmacy Revenue ($m), Split by Prescription and OTC Medication